Signal active
Bio
Philip Reilly is our Interim Chief Medical Officer and a Venture Partner at Third Rock Ventures. He is a highly respected clinical geneticist with an extensive track record in launching and building companies that seek to develop new therapies for rare genetic disorders. Dr. Reilly joined Third Rock in 2008 to focus on discovering, launching and building transformational companies dedicated to breakthrough treatments for rare diseases.
Dr. Reilly is currently a Trustee of Cornell University and is on the Board of Overseers of Weill Cornell Medical College. Prior to joining Third Rock, he was the CEO and Chairman of Interleukin Genetics, and before that, he was the Executive Director of the Eunice Kennedy Shriver Center for Mental Retardation.
He served twice (2000 and 2003) as president of the American Society of Law, Medicine and Ethics. He is a founding fellow of the American College of Medical Genetics. He has authored or co-authored more than 100 articles in scholarly journals as well as several books about clinical genetics.
Dr. Reilly has held teaching positions at Tufts University School of Medicine and Harvard Medical School. He serves on the scientific advisory board of bluebird bio and is a board observer at Edimer Pharmaceuticals.
Dr. Reilly holds an M.D. from Yale University, a J.D. from Columbia University, is a member of the Massachusetts Bar and is board certified in internal medicine and clinical genetics.
Location
Boston, Massachusetts, United States, North America
Social
Primary Organization
2007
138
62
40
51-100
Biotechnology, Health Care, Medical Device
Jobs history
1
HBM Alpha Therapeutics
Board of Directors
Invalid date - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Philip Reilly is the Venture Partner at Third Rock Ventures, based in United States, North America. With a background in Biotechnology, Philip Reilly has a rich history of leadership and innovation. Philip Reilly studied JD unknown @ Columbia University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
John Maraganore
CEO
Mark Bamforth
Operating Partner
George Church
Co-Founder
Investment portfolio
1
0
Personal investment
1
Annouced Date | Organization Name | Funding Round | Money Raised |
---|---|---|---|
Mar 01, 2023 | Thymmune Therapeutics | Seed Round - Thymmune Therapeutics | 7.0M |
Partner investment
0
There is no partner investment available on this profile
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.